US equities |
MU $931.24 ▲+1.87% NVDA $217.23 ▼-1.84% SNDK $1,394.83 ▼-0.61% AMD $562.23 ▼-1.50% SPCX $148.62 ▼-2.33% INTC $95.37 ▼-2.80% AAPL $342.00 ▼-0.28% MSFT $539.44 ▲+1.08%
FinancialContent

Articles published by Zivo Bioscience, Inc.

News headline image
Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
From Zivo Bioscience, Inc.
Via Business Wire
News headline image
ZIVO Bioscience Secures Commercial-Scale Manufacturing Agreement with Cyanotech Corporation for Zivolife™ Algal Biomass
From Zivo Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Bioscience Provides Special Letter to Shareholders
From ZIVO Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
From ZIVO Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO’s Immune-Enhancing Compounds in Poultry
From ZIVO Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
From ZIVO Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
From ZIVO Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Bioscience to Present at The Microcap Conference 2025
From Zivo Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Bioscience Reports Progress with Coccidiosis Treatment Licensing Opportunities
From Zivo Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
From Zivo Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens
From ZIVO Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
Major Global Animal Health Company Launches 42-Day Confirmatory Study with ZIVO Bioscience’s Coccidiosis Treatment in Broiler Chickens
From ZIVO Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study
From Zivo Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Bioscience Announces Uplisting to OTCQB Market
From Zivo Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
From Zivo Bioscience, Inc.
Via Business Wire
Tickers OTC ZIVO
News headline image
ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
From Zivo Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Bioscience Announces Reverse Stock Split
From Zivo Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference
From Zivo Bioscience, Inc.
Via GlobeNewswire
Tickers ZIVO ZIVOW
News headline image
Trial Results Confirm Efficacy of ZIVO Bioscience’s Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens
From Zivo Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Announces Commitment by ZWorldwide to Purchase all Zivolife™ Algal Biomass Product Produced Over the Next 18 Months
From Zivo Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Commences Sales of its Proprietary Algal Biomass as Human Food
From Zivo Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Bioscience Announces Pricing of $4.0 Million Registered Direct Offering Priced At-The-Market
From Zivo Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO’s GRAS Designation Reaffirmed for Proprietary Algal Biomass Product as a Human Food Ingredient
From Zivo Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Bioscience Receives $1 Million Bridge Financing
From Zivo Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Bioscience Announces Results of Study with its Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens
From Zivo Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Bioscience Announces Plans for a New Streamlined, Focused Corporate Structure and Establishes the ZIVOLife Agtech Business
From Zivo Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Bioscience CEO Issues Letter to Shareholders
From Zivo Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
ZIVO Reports that USDA Claims Regulatory Jurisdiction for New Coccidiosis Treatment
From ZIVO Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
Zivo Bioscience Joins Russell Microcap® Index
From ZIVO Bioscience, Inc.
Via Business Wire
Tickers ZIVO
News headline image
Zivo Bioscience Regains Compliance Following Receipt of Noncompliance Notice from Nasdaq
From ZIVO Bioscience, Inc.
Via Business Wire
Tickers ZIVO